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Abstract
Background: Until now, no long-term studies relating serum albumin level to mortality rate in prevalent
haemodialysis (HD) patients have been conducted. We aimed to examine the association between serum albumin
level and mortality over a 5-year period.
Methods: This study included 781 patients who received maintenance HD in a large, hospital-facilitated HD centre.
Five-year medical records (2009–2013) were retrospectively reviewed, and the cut-off level for serum albumin level
was set at 3.5 g/dL. The analysed albumin levels were expressed as time-averaged levels (first 24-month data) and
albumin target reach rate over the first 2-year interval. Univariate and multivariate Cox proportional hazard
regression models were used to examine the hazard function of the all-cause and cardiovascular mortality of the
study participants in the subsequent 3-year period (2011–2013).
Results: Compared to those with a 100 % albumin reach rate (3.5 g/dL), the participants with 75– < 100, 50– < 75,
and 1– < 50 % albumin reach rates exhibited significantly increased risk for all-cause mortality (HR 1.72, 95 % CI 1.
19–2.47; HR 3.14, 95 % CI 1.91–5.16; HR 3.66, 95 % CI 2.18–6.16, respectively). A similar trend for all-cause mortality
was demonstrated in participants with time-averaged albumin levels <4 g/dL (HR 1.57, 95 % CI 1.00–2.46 for 3.5–4.
0 g/dL; HR 3.66, 95 % CI 2.11–6.32 for <3.5 g/dL). Compared to a 100 % albumin reach rate, the 50– < 75 and 1– <
50 % groups (HR 4.28, 95 % CI 1.82–10.01; HR 3.23, 95 % CI 1.22–8.54 respectively) showed significantly higher
cardiovascular mortality rates. Similarly, participants with a time-averaged serum albumin level <3.5 g/dL exhibited a
higher risk for cardiovascular mortality (HR 3.24, 95 % CI: 1.23–8.56).
Conclusions: This long-term study demonstrated that higher reach rates of serum albumin levels and higher
time-averaged serum albumin levels are associated with a lower mortality rate in patients undergoing maintenance HD.
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Background
Serum albumin is commonly used as a proxy for nutritional
status, as well as a marker of inflammation. A low serum
albumin concentration is not only indicative of protein
energy wasting in dialysis patients, but it is also a powerful
predictor of the mortality risk in this population [1–4]. In
addition, there is accumulating evidence that the factors
causing the low albumin levels, rather than hypoalbuminae-
mia per se, may be associated with high mortality and mor-
bidity in dialysis patients [5, 6]. Several clinical conditions
are associated with low serum albumin levels in dialysis pa-
tients, including infectious and inflammatory diseases [7, 8],
fluid overload, inadequate dialysis [9], severe co-morbidity
[10], and taste change [11]. Thus, regular monitoring of
serum albumin levels is useful for predicting outcomes in
dialysis patients.
In previous studies, the association between the serum
albumin level and mortality in dialysis patients was
based either on a baseline serum albumin level or on a
mean level for the study period. One study that used
time-dependent 2-year longitudinal change analysis
noted that a drop in serum albumin levels during the
first 6 months was associated with an increase in all-
cause and cardiovascular mortality in the subsequent
months [2]. However, current studies are limited by their
short-term nature and relatively small sample sizes.
In the present 5-year study, we investigated the per-
centage of each patient’s serum albumin levels that
reached a pre-defined target (3.5 g/dL) during the study
period. This percentage was termed the serum albumin
reach rate in this study. We aimed to examine the asso-
ciation between time-averaged albumin and serum
albumin reach rate in the first 2-year period and the risk




Patients who received regular outpatient HD (3 times
per week) at Kaohsiung Chang Gung Memorial Hospital
in Taiwan were included in the study. The patients were
tracked from January 1, 2009 to December 31, 2013.
Patients
The records of 909 HD patients were reviewed, and 128
patients were excluded owing to incomplete demographic
and laboratory data in the study period. Finally, 781 pa-
tients were considered eligible for inclusion in the survival
analysis. Patient number of high flux HD were 672, high
efficiency HD 109. The types of vascular access were ar-
teriovenous fistula 731, Gore-Tex access 50. The
underlying kidney diseases were renal parenchymal dis-
eases (n = 156), systemic diseases (n = 392), obstructive
nephropathy (n = 6), hereditary disease (n = 4), unknown
cause (n = 221), poisoning (n = 2). During the study
period, 182 patients died and 599 patients survived.
Study design
The study was a 5-year retrospective observational
study. Serial haemogram results and biochemical data
from the study period were collected and were analysed
retrospectively. Baseline values were measured in 2009,
including haemoglobin (Hb), albumin, blood urea nitro-
gen (BUN), creatinine (Cr), potassium (K), corrected
serum calcium (Ca), phosphate (P), urea reduction ratio
(URR), intact parathyroid hormone, ferritin, Kt/V urea
(Daugirdas method) [12], and cardiothoracic (CT) ratio.
Corrected serum calcium was calculated by using the
following equation: measured total Ca (mg/dL) + 0.8
(4.0 − serum albumin [g/dL]). All blood samples were
analysed using commercial kits and an autoanalyzer
(Hitachi 7600–210, Hitachi Ltd., Tokyo, Japan). Albumin
was measured using the bromocresol green method; the
normal range was 3.5–5.2 g/dL. Chest radiography for
the measurement of the CT ratio was performed after
HD. All patients received HD with dialyzers that had an
effective surface area of >2.0 m2.
To examine the association between serum albumin
levels and mortality, we used time-averaged albumin
level and serum albumin reach rate to 3.5 g/dL in the
first 2 years (2009–2010) as the predictor variables and
all-cause mortality and cardiovascular mortality in the
subsequent 3 years (2011–2013) as outcome variables.
The time-averaged albumin level was the average of the
2-year (24 months) serum albumin level. Twenty-four or
less (censored) measurements of serum albumin levels
were observed over the first 2 years for each patient. We
defined serum albumin reach rate in the first 2 years as
the percentage of albumin levels that reached 3.5 g/dL
and the percentage of albumin levels that were ≥3.5 g/
dL. First, we stratified the albumin reach rate into 5
groups: 100 % (all 24 monthly serum albumin levels
reached 3.5 g/dL), 75– < 100, 50– < 75, 1– < 50, and 0 %
(none of the 24 monthly serum albumin levels reached
3.5 g/dL). Second, we divided the participants into 2
groups according to the percentage of monthly serum al-
bumin level recordings that were ≥3.5 g/dL over the first
2-year follow-up period: higher rate group (≥75 % serum
albumin levels were ≥3.5 g/dL) and lower rate group
(<75 % of serum albumin levels were ≥3.5 g/dL).
The protocol for the study was approved by the Com-
mittee on Human Research at Kaohsiung Chang Gung
Memorial Hospital (101-1595B) for data review and was
conducted in accordance with the Declaration of
Helsinki. Informed consent was not required from the
study patients, according to the retrospective data review
regulations of the Committee on Human Research at
Kaohsiung Chang Gung Memorial Hospital.
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Outcome measures
The outcome measures included the associations
between serum albumin reach rates (defined as the per-
centage of monthly serum albumin level recordings that
were ≥3.5 g/dL) and time-averaged albumin levels in the
first 2-year period with all-cause and cardiovascular
mortality in the subsequent 3-year period.
Statistical analysis
All statistical analyses were carried out by using STATA
(Version 11.1). For descriptive statistics, all variables
were calculated as means ± SD (standard deviation),
median with interquartile ranges, and frequency and
proportion of patients. For categorical variables, the
differences between groups were estimated using the χ2
test or Fisher’s exact test as appropriate. For continuous
variables, the differences between groups were estimated
with an independent two-sample t-test. In addition to de-
scriptive statistics, both univariate and multivariate linear
regression were used to analyse the association between
serum albumin and baseline relevant variables. The
univariate and multivariate Cox proportional hazard re-
gression model was used to estimate the hazard function
of all-cause and cardiovascular mortality for study partici-
pants, and the hazard ratios (HR), 95 % confidence inter-
vals (95 % CI), and p-values were computed. The stratified
analysis for higher albumin rate and lower albumin rate
participants was performed by using the Cox regression
Table 1 Baseline characteristics and clinical features of the study population with different albumin status (n = 781)
Variables Albumin rate reached 3.5 (g/dL) P
Lower rate (n = 92) Higher rate (n = 689)
Mean SD Mean SD
Dialysis vintage (years) 7.29 4.94 7.81 4.98 0.346
5-year mortality (n, %) <0.001
Survival 40 43.48 559 81.13
Cardiovascular 18 19.57 37 5.37
Other cause 34 36.96 93 13.50
Age (years) 66.60 11.48 58.32 11.88 <0.001
Gender (n, %) 0.066
Male 33 35.87 317 46.01
Female 59 64.13 372 53.99
Diabetes Mellitus (n, %) <0.001
No 56 60.87 540 78.37
Yes 36 39.13 149 21.63
Year of death –
Death before 2010 18 19.57 19 2.76
Death after 2010 34 36.96 111 16.11
Blood analysis
Hb (g/dL) 10.37 1.68 10.76 1.23 0.006
Albumin (g/dL) 3.43 0.30 3.95 0.27 <0.001
BUN (mg/dL) 62.67 18.74 69.26 16.12 <0.001
Cr (mg/dL) 8.75 2.22 10.89 2.19 <0.001
K (meq/L) 4.73 0.77 4.99 0.71 <0.001
Ca (mg/dL) 9.54 0.81 9.34 0.85 0.030
P (mg/dL) 4.54 1.52 4.89 1.38 0.023
iPTH (pg/mL) 163.45 (60–356) 216.10 (76–510) 0.141
Ferritin (ng/mL) 443.25 (280–714) 396.10 (231–595) 0.022
Kt/V urea 1.69 0.34 1.74 0.78 0.540
URR 0.75 0.07 0.75 0.07 0.942
Cardiothoracic ratio 0.54 0.08 0.50 0.07 <0.001
P-value for categorical variable was estimated by χ2 test and continuous variables were estimated by two-sample t-test
Abbreviations: URR urea reduction ratio
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model. In all analyses, a p-value < 0.05 is considered statis-
tically significant.
Results
A total of 781 patients were enrolled for the analysis.
Among them, 689 patients had higher albumin reach
rates and 92 patients had lower albumin reach rates over
the 5-year period. Older age and higher prevalence of
diabetes were identified in the patients with lower albu-
min reach rates. Patients with higher albumin reach
rates exhibited higher survival rates than those with
lower albumin reach rates. In terms of haemogram and
biophysical parameters, patients with lower albumin
reach rates exhibited significantly lower values for albu-
min, BUN, Cr, K, and P and higher levels of Ca, ferritin,
and CT ratio than those with higher albumin reach rates
(Table 1).
The univariate and multivariate regression analysis be-
tween baseline serum albumin level and relevant vari-
ables is shown in Table 2. In the univariate regression
analysis, baseline albumin level had a statistically signifi-
cant inverse association with age, female sex, diabetes,
Ca level, and CT ratio. For female sex participants, the
predicted serum albumin levels would be 0.11 g/dL
lower than for males. Likewise, the predicted serum
albumin levels of diatebes participants would be 0.08 g/dL
lower than non-diabetes participants. Moreover, baseline
albumin level had a statistically significant positive as-
sociation with Hb, BUN, Cr, K, and P levels. In the
multivariate regression analysis, baseline albumin level
had a statistically significant inverse association with
age, and a positive association with Hb, Cr, K, ferritin
levels, and URR.
Table 3 shows the distribution of the study population
in different albumin categories (using 2-year serum
albumin measurement) as well as by mortality based on
the different serum albumin categories. The percentage
of all-cause mortality and cardiovascular mortality over
the 3-year period was significantly higher with lower
Table 2 Univariate and multivariate regression analysis between
baseline serum albumin levels and relevant variables
Variable Betaa Pa Betab Pb
Dialysis vintage (years) 0.01 0.709 −0.03 0.41
Age (years) −0.29 <0.001 −0.17 0.00
Gender (Female) −0.11 0.002 0.02 0.61
Diabetes Mellitus −0.08 0.021 0.01 0.87
Hb (g/dL) 0.24 <0.001 0.18 0.00
BUN (mg/dL) 0.20 <0.001 −0.02 0.57
Cr (mg/dL) 0.39 <0.001 0.29 0.00
K (meq/L) 0.22 <0.001 0.16 0.00
Ca (mg/dL) −0.09 0.015 −0.03 0.34
P (mg/dL) 0.16 <0.001 0.05 0.19
iPTH (pg/mL) 0.01 0.738 −0.03 0.41
Ferritin (ng/mL) −0.05 0.162 0.07 0.04
Kt/V urea <0.01 0.946 0.00 0.91
URR −0.02 0.551 0.08 0.04
Cardiothoracic ratio −0.15 <0.001 −0.03 0.37
aUnivariate regression analysis
bMultivariate regression analysis
Table 3 Different albumin categories using 2-year serum albumin measurement in the study population
Albumin group Total All-cause mortality Cardiovascular mortality
n % n %a P n %b P
Time-averaged serum albumin <0.001* <0.001*
≥4 g/dL 235 30.09 25 10.64 8 3.40
3.5– < 4 g/dL 474 60.69 115 24.26 33 7.00
<3.5 g/dL 72 9.22 42 58.33 14 19.44
Albumin rate reached 3.5 (g/dL) <0.001** <0.001**
100 % 487 62.36 67 13.76 19 3.90
75 to <100 % 202 25.86 63 31.19 18 8.91
50 to <75 % 46 5.89 23 50.00 9 19.56
1 to <50 % 38 4.87 24 63.16 7 18.42
0 8 1.02 5 62.50 2 25.00
Albumin rate reached 3.5 (g/dL) <0.001* <0.001*
Higher rate (75–100 %) 689 88.22 130 18.87 37 5.37
Lower rate (0– < 75 %) 92 11.78 52 56.52 18 19.56
*: χ2 test
**: Fisher’s exact test
a(number of all-cause mortality/total number in each category) × 100 %
b(number of cardiovascular mortality/total number in each category) × 100 %
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time-averaged serum albumin level and with lower albu-
min reach rates over the first 2-year period.
The Cox regression survival analysis shown in Table 4
demonstrates the associations between different albumin
categories (using the first 2-year serum albumin meas-
urement) and all-cause and cardiovascular mortality over
the subsequent 3-year period. The 100 % albumin reach
rate, higher reach rate, and time-averaged serum
Table 4 Associations between different albumin categories using 2-year serum albumin measurements with all-cause and cardiovascular
mortality in the study population
Albumin category All-cause mortality
Unadjusted Adjusted Adjusted
(demographic)
HR 95 % CI P HR 95 % CI P HR 95 % CI P
Albumin rate reached 3.5
(g/dL)
100 % Reference Reference Reference
75 to < 100 % 2.41 1.70–3.43 <0.001 2.01 1.41–2.87 <0.001 1.72 1.19–2.47 0.004
50 to < 75 % 5.82 3.61–9.37 <0.001 3.64 2.22–5.95 <0.001 3.14 1.91–5.16 <0.001
1 to < 50 % 7.20 4.43–11.69 <0.001 4.95 3.00–8.16 <0.001 3.66 2.18–6.16 <0.001
0 8.10 3.25–20.14 <0.001 4.80 1.90–12.15 0.001 2.54 0.96–6.76 0.062
Albumin rate reached 3.5
(g/dL)
Higher rate (75–100 %) Reference Reference Reference
Lower rate (0– < 75 %) 4.45 3.22–6.14 <0.001 3.11 2.23–4.35 <0.001 2.55 1.79–3.63 <0.001
Time-averaged serum
albumin
≥4 Reference Reference Reference
3.5 to < 4 2.38 1.54–3.68 <0.001 1.80 1.15–2.81 0.010 1.57 1.00–2.46 0.051
<3.5 8.71 5.28–14.37 <0.001 4.84 2.84–8.26 <0.001 3.66 2.11–6.32 <0.001
Albumin rate reached 3.5
(g/dL)
100 % Reference Reference Reference
75 to < 100 % 2.32 1.18–4.54 0.015 1.99 1.01–3.93 0.046 1.73 0.86–3.48 0.124
50 to < 75 % 7.88 3.53–17.58 <0.001 4.78 2.09–10.96 <0.001 4.28 1.82–10.01 0.001
1 to < 50 % 7.75 3.23–18.62 <0.001 4.69 1.91–11.49 0.001 3.23 1.22–8.54 0.018
0 10.38 2.40–44.91 0.002 6.59 1.47–29.61 0.014 4.08 0.86–19.39 0.077
Albumin category Cardiovascular mortality
Unadjusted Adjusted Adjusted
(demographic)
HR 95 % CI P HR 95 % CI P HR 95 % CI P
Albumin rate reached 3.5
(g/dL)
Higher rate (75–100 %) Reference Reference Reference
Lower rate (0– < 75 %) 5.88 3.31–10.45 <0.001 3.66 2.01–6.68 <0.001 2.94 1.58–5.47 0.001
Time-averaged serum
albumin
≥4 Reference Reference Reference
3.5 to < 4 2.02 0.93–4.42 0.076 1.51 0.68–3.36 0.315 1.28 0.57–2.90 0.552
<3.5 8.94 3.74–21.37 <0.001 4.61 1.82–11.63 0.001 3.24 1.23–8.56 0.018
Univariate and multivariate Cox proportional hazard regression model
Adjusted (demographic), the adjusted covariates including dialysis vintage, age, sex, and diabetes mellitus
Adjusted, the adjusted covariates including dialysis vintage, age, sex, diabetes mellitus, and all laboratory blood analysis values
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albumin ≥4 were set as the references. Compared to a
100 % albumin reach rate the 75– < 100, 50– < 75, and
1– < 50 % albumin reach rates exhibited significant in-
creased risk in all-cause mortality according to the total
adjusted analysis (HR 1.72, 95 % CI 1.19–2.47; HR 3.14,
95 % CI 1.91–5.16; and HR 3.66, 95 % CI 2.18–6.16,
respectively) A similar trend in all-cause mortality was
demonstrated with higher rate albumin reach (75–100 %)
and higher time-averaged albumin levels. Compared to a
100 % albumin reach rate, 50– < 75 and 1– < 50 % reach
rates were associated with significantly higher cardiovascu-
lar mortality (HR 4.28, 95 % CI 1.82–10.01 and HR 3.23,
95 % CI 1.22–8.54, respectively). Similarly, time-averaged
serum albumin levels <3.5 g/dL conferred higher risk of
cardiovascular mortality (HR 3.24, 95 % CI: 1.23–8.56)
(Table 4).
Discussion
Serum albumin level is recognized as a strong predictor
of mortality in HD patients [1–4]. However, serum albu-
min levels in routine blood tests are known to undergo
dynamic changes. Therefore, a majority of clinical stud-
ies have used baseline levels, mean levels during a short-
term period, or time-varying albumin levels to predict
the risk of mortality in HD patients [1–4]. The present
study investigated the association of 2-year serum albu-
min levels with mortality in a longitudinal 3-year period
by utilizing the serum albumin reach rate for a pre-
defined target level and the time-averaged albumin level.
The cut-off serum albumin level was set at 3.5 g/dL,
based on the lower normality limit in our laboratory
test and the minimal requirement of the nutritional
quality by the National Health Insurance Administra-
tion in Taiwan (http://sc-dr.tw/news/104/010603.htm)
(http://sc-dr.tw/news/104/01/01060301.pdf ). The study
demonstrated that HD patients who reached the target
serum albumin levels more frequently and who had higher
time-averaged albumin levels over a 2-year period had a
survival advantage in the subsequent 3-year period.
In this study, the baseline serum albumin level was
found to be inversely associated with age, female sex,
diabetes, Ca level, and CT ratio. Furthermore, the base-
line serum albumin was found to be positively associated
with, Hb, BUN, Cr, K, and P levels through univariate
regression analysis. However, age was the only factor
found to be inversely associated by multivariate regres-
sion analysis. A plausible explanation is that age is asso-
ciated with a greater risk of disability and as well as
limitation of oral intake. These conditions can result in
protein malnutrition and a low albumin level.
Multivariate regression analysis showed that baseline
serum albumin level was positively associated with Hb,
Cr, K, ferritin levels, and URR. This is consistent with a
previous study on a cohort of HD patients, which
showed the association of 3-month average serum albu-
min levels with Hb and Cr levels [2]. It is reasonable to
assume that patients with higher Hb levels may have
greater activity levels and thus higher dietary intake. Fur-
thermore, a higher serum Cr level potentially reflects a
higher muscle mass and indicates a healthy nutritional
status. It is also reasonable to assume that free access to
dietary intake may result in a positive association of
serum albumin level with serum K levels.
The adequacy of dialysis is critical for predicting morbid-
ity and mortality among HD patients. One retrospective
study of approximately 10,000 HD patients found that
lower urea reduction ratios during dialysis were associated
with increased risk of death; the risk was increased owing
to inadequate nutrition [9]. Another study of 1600 HD
patients concluded that, after reaching adequacy targets
(Kt/V urea, URR), the main determinants of survival were
nutrition status and age [13]. Our participants had adequate
Kt/V urea scores, and a majority had adequate URR. Fur-
thermore, a positive association was observed between
URR and the baseline serum albumin level. Accordingly,
our results are consistent with the previous findings that
URR and serum albumin level may contribute to the risk of
death in HD patients.
Previous studies have reported the association of
serum albumin levels with mortality in dialysis patients
[1–4, 7, 10]. However, most of the studies had short-
term observational designs with durations between 1 and
2 years. Moreover, the outcome measures in prior studies
were the baseline albumin level or the time-varying/aver-
age albumin level during the study period. In an earlier
study with a follow-up of 1.25 years, baseline serum
albumin level was found to be a strong predictor of death
in chronic HD patients [1]. Another study with a 10-year
observation period also showed that reduced baseline
serum albumin level was an independent predictor of
mortality in incident dialysis patients [10]. One study used
trimonthly-varying serum albumin level and baseline albu-
min level to predict the mortality in HD patients over a 2-
year follow-up period. The study demonstrated that the
hazard ratios for cardiovascular death increase across dec-
rements of baseline serum albumin levels; however, the
hazard ratios of cardiovascular death did not differ with
time-varying albumin levels <3.8 g/dL [2].
The present study is the first to utilize the serum albu-
min reach rate in prevalent HD patients. In addition, this
study had a longer observational period than previous
studies. We found that higher albumin reach rate and
time-averaged serum albumin level over a 2-year period
are associated with lower all-cause mortality over a 3-year
follow-up period. A similar trend was also observed in as-
sociation with cardiovascular mortality.
While most studies have investigated the association
of serum albumin levels with all-cause mortality or
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cardiovascular mortality, one study conducted in Canadian
HD patients found that the serum albumin levels were as-
sociated with septicaemia and hospitalization in patients
with infectious diseases [7]. In the present study, we did
not determine the exact cause of mortality; therefore, the
weight contribution of septicaemia in all-cause mortality
was not ascertained. Taken together, the results of the
previous studies and that of our present study were
consistent with regards to the association between
serum albumin levels and mortality in dialysis patients,
with either time-averaged albumin levels or albumin
reach rate used as predictors.
Although the present study showed a significant asso-
ciation between low serum albumin levels and mortality
in prevalent HD patients, chance findings cannot be
completely excluded. Retrospectively selecting partici-
pants from one large HD centre may have influenced
the results. Therefore, the association between the pre-
dictor variables and mortality may be overestimated.
Furthermore, the present study did not investigate the
contributions of inflammation, comorbidities, and nutri-
tional status. Finally, we used albumin reach percentage
in the first 2 years and time-averaged albumin level to
predict mortality in the subsequent 3 years in our HD
patients. However, there still exists a drawback for fully
evaluation the exposure (albumin level) and mortality in
our HD patients. A well-designed, prospective study is
needed to overcome the drawback in retrospective study
in the future.
Conclusions
The present study indicates that a higher serum albumin
level has a survival benefit in long-term HD patients.
An obviously low albumin level should emphasize the
need for initiating a management strategy and receiving
appropriate medical intervention.
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